ALPHA Stock Overview
Pharnext SA, a clinical-stage biopharmaceutical company, engages in the development of therapies for neurodegenerative diseases with high unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Pharnext SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.15 |
| 52 Week High | €80,400,000.00 |
| 52 Week Low | €0.14 |
| Beta | -316.97 |
| 1 Month Change | -40.36% |
| 3 Month Change | -92.52% |
| 1 Year Change | -100.00% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
| ALPHA | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -17.7% | -3.9% | -0.03% |
| 1Y | -100.0% | -11.7% | 1.8% |
Return vs Industry: ALPHA underperformed the French Biotechs industry which returned -12.1% over the past year.
Return vs Market: ALPHA underperformed the French Market which returned 1.7% over the past year.
Price Volatility
| ALPHA volatility | |
|---|---|
| ALPHA Average Weekly Movement | 62.2% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.7% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALPHA's share price has been volatile over the past 3 months.
Volatility Over Time: ALPHA's weekly volatility has decreased from 140014% to 62% over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Hugo Brugiere | pharnext.com |
Pharnext SA, a clinical-stage biopharmaceutical company, engages in the development of therapies for neurodegenerative diseases with high unmet medical needs. Its products include PXT3003, a novel fixed-dose synergistic combination of baclofen, naltrexone, and sorbitol formulated that is in Phase III clinical trials for the treatment of Charcot-Marie-tooth disease type 1A; and PXT864 to treat amyotrophic lateral sclerosis. The company was incorporated in 2007 and is headquartered in Paris, France.
Pharnext SA Fundamentals Summary
| ALPHA fundamental statistics | |
|---|---|
| Market cap | €26.03k |
| Earnings (TTM) | -€31.55m |
| Revenue (TTM) | €1.82m |
0.0x
P/S Ratio0.0x
P/E RatioIs ALPHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALPHA income statement (TTM) | |
|---|---|
| Revenue | €1.82m |
| Cost of Revenue | €0 |
| Gross Profit | €1.82m |
| Other Expenses | €33.37m |
| Earnings | -€31.55m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -181.47 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,733.56% |
| Debt/Equity Ratio | -79.0% |
How did ALPHA perform over the long term?
See historical performance and comparison